Cargando…
HLA-DR7 and HLA-DQ2: Transgenic mouse strains tested as a model system for ximelagatran hepatotoxicity
The oral thrombin inhibitor ximelagatran was withdrawn in the late clinical trial phase because it adversely affected the liver. In approximately 8% of treated patients, drug-induced liver injury (DILI) was expressed as transient alanine transaminase (ALT) elevations. No evidence of DILI had been re...
Autores principales: | Lundgren, Hanna, Martinsson, Klara, Cederbrant, Karin, Jirholt, Johan, Mucs, Daniel, Madeyski-Bengtson, Katja, Havarinasab, Said, Hultman, Per |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5608249/ https://www.ncbi.nlm.nih.gov/pubmed/28934241 http://dx.doi.org/10.1371/journal.pone.0184744 |
Ejemplares similares
-
A Triple-Transgenic Immunotolerant Mouse Model
por: Brenden, Nina, et al.
Publicado: (2013) -
Peptide binding predictions for HLA DR, DP and DQ molecules
por: Wang, Peng, et al.
Publicado: (2010) -
Association of HLA-DR/DQ polymorphisms with schizophrenia in Tunisian patients
por: Sayeh, Aicha, et al.
Publicado: (2014) -
Immunogenetic Study of Diabetes Mellitus in Relation to HLA DQ and DR
por: Singh, Gyanendra, et al.
Publicado: (2020) -
The incidence of HLA-DQ2/DQ8 in Turkish children with celiac disease and a comparison of the geographical distribution of HLA-DQ
por: Basturk, Ahmet, et al.
Publicado: (2017)